WILMINGTON, Delaware, April 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

Efzimfotase alfa demonstrated positive results from global Phase III clinical program in hypophosphatasia

MULBERRY randomized, placebo-controlled trial showed efzimfotase alfa demonstrated statistically significant and clinically meaningful improvement in bone health in treatment-naive pediatric patients

CHESTNUT randomized, open- . . .

Click here for more information about our products